Analysts See $-0.50 EPS for XOMA (XOMA); 51job Ads (JOBS) Shorts Increased By 0.02%

February 17, 2018 - By Adrian Erickson

Analysts expect XOMA Corporation (NASDAQ:XOMA) to report $-0.50 EPS on March, 15.They anticipate $2.39 EPS change or 82.70% from last quarter’s $-2.89 EPS. After having $1.98 EPS previously, XOMA Corporation’s analysts see -125.25% EPS growth. The stock decreased 2.56% or $0.68 during the last trading session, reaching $25.9. About 188,698 shares traded or 2.37% up from the average. XOMA Corporation (NASDAQ:XOMA) has declined 51.66% since February 17, 2017 and is downtrending. It has underperformed by 68.36% the S&P500.

51job Incorporated Ads (NASDAQ:JOBS) had an increase of 0.02% in short interest. JOBS’s SI was 1.91 million shares in February as released by FINRA. Its up 0.02% from 1.91M shares previously. With 267,700 avg volume, 7 days are for 51job Incorporated Ads (NASDAQ:JOBS)’s short sellers to cover JOBS’s short positions. The SI to 51job Incorporated Ads’s float is 9.12%. The stock increased 1.01% or $0.68 during the last trading session, reaching $67.85. About 150,699 shares traded. 51job, Inc. (NASDAQ:JOBS) has risen 53.60% since February 17, 2017 and is uptrending. It has outperformed by 36.90% the S&P500.

Among 2 analysts covering 51job (NASDAQ:JOBS), 1 have Buy rating, 0 Sell and 1 Hold. Therefore 50% are positive. 51job had 3 analyst reports since August 12, 2015 according to SRatingsIntel. Macquarie Research maintained 51job, Inc. (NASDAQ:JOBS) rating on Wednesday, August 12. Macquarie Research has “Neutral” rating and $31 target. The company was upgraded on Friday, August 4 by Macquarie Research. The firm earned “Neutral” rating on Thursday, November 12 by Citigroup.

51job, Inc., through its subsidiaries, provides integrated human resource services in the People's Republic of China. The company has market cap of $4.19 billion. The firm provides recruitment advertising services, including online recruitment services through its Websites comprising 51job.com, yingjiesheng.com, and 51jingying.com; and print advertising services through 51job Weekly, a city-specific recruitment advertising publication. It has a 95.43 P/E ratio. It also offers other human resource related services, such as business process outsourcing that consist of social insurance and benefits processing, regulatory compliance with local governmental employment regulations, and payroll processing; and conducts training seminars in business management, leadership, sales and marketing, human resource, negotiation skills, financial planning and analysis, public administration, manufacturing, secretarial, and other skills.

XOMA Corporation discovers, develops, and commercializes antibody therapeutics in the United States, Europe, and the Asia Pacific. The company has market cap of $210.93 million. The company's product candidates include X358, a human negative allosteric modulating insulin receptor antibody that is in Phase II proof-of-concept study for the treatment of patients with hypoglycemia due to congenital hyperinsulinism and hypoglycemia in post-bariatric surgery patients; X213, a allosteric inhibitor for the treatment of prolactinoma and anti-psychotic-induced hyperprolactinemia; and X129, a potent fragment of a monoclonal antibody for the treatment of patients with acute severe hypoglycemia. It currently has negative earnings. The Company’s preclinical product candidates comprise interleukin 2 for the treatment of metastatic melanoma and renal cell carcinoma; and anti-parathyroid receptor, a G-protein-coupled receptor for the treatment of hyperparathyroidism and humoral hypercalcemia of malignancy.

Among 7 analysts covering Xoma Limited (NASDAQ:XOMA), 2 have Buy rating, 0 Sell and 5 Hold. Therefore 29% are positive. Xoma Limited had 22 analyst reports since July 23, 2015 according to SRatingsIntel. The firm has “Buy” rating given on Tuesday, November 14 by H.C. Wainwright. Wedbush maintained XOMA Corporation (NASDAQ:XOMA) rating on Tuesday, February 6. Wedbush has “Buy” rating and $33.0 target. On Monday, August 14 the stock rating was maintained by Wedbush with “Hold”. H.C. Wainwright maintained XOMA Corporation (NASDAQ:XOMA) on Thursday, December 7 with “Buy” rating. H.C. Wainwright reinitiated it with “Buy” rating and $38 target in Tuesday, October 17 report. The stock of XOMA Corporation (NASDAQ:XOMA) earned “Neutral” rating by Ladenburg Thalmann on Wednesday, July 22. The rating was downgraded by Zacks on Friday, August 28 to “Buy”. The stock of XOMA Corporation (NASDAQ:XOMA) earned “Buy” rating by H.C. Wainwright on Thursday, January 18. As per Monday, November 14, the company rating was downgraded by Wedbush. The firm has “Buy” rating by Wedbush given on Wednesday, August 5.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: